The US based company plans to use the proceeds to fund the continued development and commercial supply of its diversified portfolio of advanced drug delivery systems and other general corporate purposes.
Expected to close on 21November 2011, the public offering is subject to customary closing conditions.
According to the company, Jefferies & Company is acting as sole book-running manager for the offering while Leerink Swann LLC is acting as co-lead manager.
